Table 1.
WHO subtype
|
All cases | |||
---|---|---|---|---|
ALK-positive | ALK-negative* | Primary cutaneous** | ||
N | 22 | 62 | 32 | 116 |
Age (years) | ||||
Mean | 29 | 62 | 62 | 56 |
Range | 6–74 | 24–87 | 13–93 | 6–93 |
Sex | ||||
Male | 18 | 40 | 17 | 75 |
Female | 4 | 22 | 15 | 41 |
Genetics | ||||
DUSP22 rearrangement | ||||
Present | 0 | 19 | 13 | 32 |
Absent | 20 | 43 | 19 | 82 |
Not done | 2 | 0 | 0 | 2 |
TP63 rearrangement | ||||
Present | 0 | 8 | 2 | 10 |
Absent | 22 | 54 | 30 | 106 |
Not done | 0 | 0 | 0 | 0 |
Abbreviations: ALCL: anaplastic large cell lymphoma; ALK: anaplastic lymphoma kinase; WHO: World Health Organization.
In 1 case of systemic ALK-negative ALCL the specimen available for analysis was a skin biopsy, though the patient had documented systemic disease.
In 3 cases of primary cutaneous ALCL the specimens available for analysis were locoregional lymph nodes, though the patients had documented primary cutaneous disease.